On Wednesday, BriaCell Therapeutics BCTX inventory traded greater with a session quantity of 113.08 million, in comparison with the typical quantity of 366.19 thousand, in keeping with knowledge from Benzinga Professional.
BriaCell Therapeutics introduced total survival knowledge from its Section 2 scientific research of Bria-IMT together with an immune checkpoint inhibitor (CPI) in late-stage metastatic breast most cancers.
The corporate reported a median total survival of 15.6 months from its most up-to-date sufferers (handled since 2022) vs. 6.7-9.3 months for related sufferers reported within the literature.
These sufferers are being handled with the identical Bria-IMT formulation at the moment being utilized in BriaCell’s ongoing Section 3 pivotal research in metastatic breast most cancers.
This represents a considerable enchancment over BriaCell’s 13.4 months median total survival beforehand reported in December 2023.
“The Bria-IMT routine is the one investigational drug we’ve seen to point out these spectacular survival numbers in closely pre-treated metastatic breast most cancers sufferers who’ve failed quite a few prior remedies, together with immune checkpoint inhibitors and antibody-drug conjugates,” said Giuseppe Del Priore, BriaCell’s Chief Medical Officer.”
The Section 2 research enrolled 54 closely pre-treated metastatic breast most cancers sufferers (common variety of prior remedies = 6) who have been handled with the Bria-IMT routine and an immune checkpoint inhibitor.
Worth Motion: BCTX inventory is up 213.1% at $1.94 eventually verify Wednesday.
Learn Subsequent:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
